Acura Pharmaceuticals Company Profile (NASDAQ:ACUR)

About Acura Pharmaceuticals

Acura Pharmaceuticals logoAcura Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. The Company has discovered and developed three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its third deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidently or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine into methamphetamine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Delivery
  • Sub-Industry: Pharmaceuticals
  • Exchange: NASDAQ
  • Symbol: ACUR
  • CUSIP: 00509L70
Key Metrics:
  • Previous Close: $1.67
  • 50 Day Moving Average: $1.883
  • 200 Day Moving Average: $2.292
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -28.50
  • P/E Growth: 0.000
  • Market Cap: $20.31M
  • Outstanding Shares: 11,833,000
  • Beta: 1.72
Additional Links:
Companies Related to Acura Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Acura Pharmaceuticals (NASDAQ:ACUR) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $8.00 (367.84% upside)

Analysts' Ratings History for Acura Pharmaceuticals (NASDAQ:ACUR)
Show:
DateFirmActionRatingPrice TargetDetails
8/11/2016FBR & CoReiterated RatingBuy$10.00View Rating Details
4/13/2016Roth CapitalReiterated RatingBuy$6.00View Rating Details
7/2/2015MLV & Co.Initiated CoverageBuy$2.00View Rating Details
(Data available from 8/24/2014 forward)

Earnings

Earnings History for Acura Pharmaceuticals (NASDAQ:ACUR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/8/2016Q2($0.28)($0.28)ViewN/AView Earnings Details
5/2/2016Q116($0.26)($0.28)ViewN/AView Earnings Details
2/29/2016Q315($0.03)($0.08)$2.70 million$2.68 millionViewListenView Earnings Details
8/3/2015Q215($0.02)($0.05)$2.90 millionViewN/AView Earnings Details
5/4/2015Q115$0.07$0.03$7.60 million$5.40 millionViewN/AView Earnings Details
3/2/2015Q414($0.09)($0.06)ViewN/AView Earnings Details
11/3/2014($0.08)($0.06)ViewN/AView Earnings Details
8/6/2014($0.08)($0.07)ViewN/AView Earnings Details
5/5/2014($0.05)($0.08)ViewN/AView Earnings Details
3/3/2014Q4 13($0.06)($0.29)ViewN/AView Earnings Details
8/1/2013Q2 2013($0.07)ViewN/AView Earnings Details
3/4/2013Q4 2012($0.86)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Acura Pharmaceuticals (NASDAQ:ACUR)
Current Year EPS Consensus Estimate: $-1.02 EPS
Next Year EPS Consensus Estimate: $-0.06 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.20)($0.20)($0.20)
Q2 20162($0.28)($0.27)($0.28)
Q3 20162($0.28)($0.17)($0.23)
Q4 20162($0.28)($0.20)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Acura Pharmaceuticals (NASDAQ:ACUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Acura Pharmaceuticals (NASDAQ:ACUR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/17/2015Claudius LlcMajor ShareholderSell104,823$1.08$113,208.84View SEC Filing  
1/12/2015Claudius LlcMajor ShareholderSell171,000$0.62$106,020.00View SEC Filing  
5/22/2014William G SkellyDirectorSell4,600$1.23$5,658.00View SEC Filing  
5/20/2014William G SkellyDirectorSell5,000$1.21$6,050.00View SEC Filing  
5/19/2014Albert W BrzeczkoVPBuy2,000$1.20$2,400.00View SEC Filing  
5/16/2014Bruce F WessonDirectorBuy80,000$1.13$90,400.00View SEC Filing  
5/16/2014James F EmighVPBuy15,000$1.21$18,150.00View SEC Filing  
5/16/2014Peter A ClemensCFOBuy3,000$1.21$3,630.00View SEC Filing  
5/14/2014William G SkellyDirectorSell2,900$1.21$3,509.00View SEC Filing  
5/12/2014William G SkellyDirectorSell5,000$1.25$6,250.00View SEC Filing  
5/8/2014William G SkellyDirectorSell2,500$1.30$3,250.00View SEC Filing  
3/3/2014Claudius LlcMajor ShareholderSell2,500$2.00$5,000.00View SEC Filing  
2/28/2014Claudius LlcMajor ShareholderSell351,260$2.02$709,545.20View SEC Filing  
2/24/2014Claudius LlcMajor ShareholderSell44,019$1.97$86,717.43View SEC Filing  
11/25/2013Albert W BrzeczkoVPBuy1,215$1.70$2,065.50View SEC Filing  
10/10/2013Claudius LlcMajor ShareholderSell4,200$2.05$8,610.00View SEC Filing  
8/27/2013William G SkellyDirectorSell2,000$1.55$3,100.00View SEC Filing  
7/15/2013Care Capital Ii LlcMajor ShareholderSell31,610$2.04$64,484.40View SEC Filing  
7/3/2013Care Capital Ii LlcMajor ShareholderSell14,200$2.00$28,400.00View SEC Filing  
7/2/2013Claudius LlcMajor ShareholderSell200,000$2.15$430,000.00View SEC Filing  
6/27/2013Care Capital Ii LlcMajor ShareholderSell76,281$2.01$153,324.81View SEC Filing  
6/24/2013Care Capital Ii LlcMajor ShareholderSell83,000$2.03$168,490.00View SEC Filing  
6/19/2013Care Capital Ii LlcMajor ShareholderSell114,000$2.12$241,680.00View SEC Filing  
6/17/2013Claudius LlcMajor ShareholderSell20,446$2.15$43,958.90View SEC Filing  
6/14/2013Care Capital Ii LlcMajor ShareholderSell90,000$2.16$194,400.00View SEC Filing  
6/11/2013Care Capital Ii LlcMajor ShareholderSell102,000$2.19$223,380.00View SEC Filing  
6/10/2013Claudius LlcMajor ShareholderSell21,496$2.20$47,291.20View SEC Filing  
6/6/2013Claudius LlcMajor ShareholderSell39,453$2.19$86,402.07View SEC Filing  
6/3/2013Care Capital Ii LlcMajor ShareholderSell148,000$2.24$331,520.00View SEC Filing  
5/31/2013Claudius LlcMajor ShareholderSell31,559$2.25$71,007.75View SEC Filing  
5/29/2013Care Capital Ii LlcMajor ShareholderSell108,701$2.33$253,273.33View SEC Filing  
5/28/2013William G SkellyDirectorSell2,000$2.40$4,800.00View SEC Filing  
5/23/2013Care Capital Ii LlcMajor ShareholderSell252,000$2.31$582,120.00View SEC Filing  
5/22/2013William G SkellyDirectorSell4,000$2.33$9,320.00View SEC Filing  
5/21/2013Claudius LlcMajor ShareholderSell47,410$2.30$109,043.00View SEC Filing  
5/20/2013Care Capital Ii LlcMajor ShareholderSell510,000$2.36$1,203,600.00View SEC Filing  
5/16/2013Care Capital Ii LlcMajor ShareholderSell662,000$2.38$1,575,560.00View SEC Filing  
5/16/2013William G SkellyDirectorSell3,000$2.25$6,750.00View SEC Filing  
5/15/2013Claudius LlcMajor ShareholderSell183,434$2.33$427,401.22View SEC Filing  
5/13/2013Care Capital Ii LlcMajor ShareholderSell259,000$2.19$567,210.00View SEC Filing  
5/9/2013William G SkellyDirectorSell3,000$2.20$6,600.00View SEC Filing  
4/11/2013Claudius LlcMajor ShareholderSell121,454$2.23$270,842.42View SEC Filing  
3/26/2013Care Capital Ii LlcMajor ShareholderSell39,554$2.17$85,832.18View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Acura Pharmaceuticals (NASDAQ:ACUR)
DateHeadline
capitalcube.com logoETF’s with exposure to Acura Pharmaceuticals, Inc. : August 18, 2016 (NASDAQ:ACUR)
www.capitalcube.com - August 18 at 8:44 PM
finance.yahoo.com logoACURA PHARMACEUTICALS, INC Financials (NASDAQ:ACUR)
finance.yahoo.com - August 17 at 3:19 PM
4-traders.com logoACURA PHARMACEUTICALS, INC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K) (NASDAQ:ACUR)
www.4-traders.com - August 16 at 8:37 PM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or (NASDAQ:ACUR)
biz.yahoo.com - August 16 at 8:37 PM
capitalcube.com logoAcura Pharmaceuticals, Inc. :ACUR-US: Earnings Analysis: Q2, 2016 By the Numbers : August 15, 2016 (NASDAQ:ACUR)
www.capitalcube.com - August 15 at 3:20 PM
News IconStock Update on Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) - Duncan Research (NASDAQ:ACUR)
www.duncanindependent.com - August 11 at 3:20 PM
reuters.com logoBRIEF-Acura Pharmaceuticals qtrly loss per share $0.28 - Reuters (NASDAQ:ACUR)
www.reuters.com - August 9 at 3:36 PM
4-traders.com logoACURA PHARMACEUTICALS, INC : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) (NASDAQ:ACUR)
www.4-traders.com - August 9 at 12:03 PM
reuters.com logoBRIEF-Acura Pharmaceuticals qtrly loss per share $0.28 (NASDAQ:ACUR)
www.reuters.com - August 9 at 12:03 PM
twst.com logoAcura Pharmaceuticals Inc.: Acura Pharmaceuticals Announces Second Quarter 2016 Financial Results (NASDAQ:ACUR)
www.twst.com - August 9 at 12:03 PM
twst.com logoAcura Pharmaceuticals Inc.: Acura Pharmaceuticals Announces Second Quarter 2016 Financial Results - The Wall Street Transcript (NASDAQ:ACUR)
www.twst.com - August 8 at 8:45 PM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements an (NASDAQ:ACUR)
biz.yahoo.com - August 8 at 8:45 PM
publicnow.com logoAcura Pharmaceuticals Announces Second Quarter 2016 Financial Results (NASDAQ:ACUR)
www.publicnow.com - August 8 at 8:45 PM
finance.yahoo.com logoWhat Awaits ACUR & Other Drug Stocks this Earnings Season? (NASDAQ:ACUR)
finance.yahoo.com - July 29 at 9:43 AM
realistinvestor.com logoAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Yearly Accounts Payable At $0.11 Millions - RealistInvestor.com (NASDAQ:ACUR)
www.realistinvestor.com - July 28 at 11:55 AM
News IconShares Losing Ground in Trade: Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) - TGP (NASDAQ:ACUR)
telanaganapress.com - July 21 at 3:19 PM
News IconStock Bending Down in Today's Session: Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) - TGP (NASDAQ:ACUR)
telanaganapress.com - July 20 at 10:10 PM
news.cmlviz.com logoAcura Pharmaceuticals Inc Stock Technicals Hit Weakness - CML News (NASDAQ:ACUR)
news.cmlviz.com - July 20 at 3:48 PM
realistinvestor.com logoAccounts Payable For Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) Stood At $0.375 - RealistInvestor.com (NASDAQ:ACUR)
www.realistinvestor.com - July 20 at 3:48 PM
ftsenews.co.uk logoNew Broker Ratings For Acura Pharmaceuticals, Inc. (ACUR) - FTSE News (NASDAQ:ACUR)
www.ftsenews.co.uk - July 16 at 3:19 PM
News IconAcura Pharmaceuticals Incorporated (NASDAQ:ACUR) Sellers Increased By 60.19% Their Shorts - Consumer Eagle (NASDAQ:ACUR)
www.consumereagle.com - July 14 at 3:20 PM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 8-K, Regulation FD Disclosure (NASDAQ:ACUR)
biz.yahoo.com - July 13 at 4:07 PM
twst.com logoAcura Pharmaceuticals Inc.: Acura Pharmaceuticals to Host Webcast on July 14, 2016 to Discuss Additional Data From ... - The Wall Street Transcript (NASDAQ:ACUR)
www.twst.com - July 13 at 3:19 PM
News IconShare Volatility Watch for: Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) - Engelwood Daily (NASDAQ:ACUR)
www.engelwooddaily.com - July 13 at 3:19 PM
finance.yahoo.com logoAcura Pharmaceuticals to Host Webcast on July 14, 2016 to Discuss Additional Data From Study AP-LTX-400 - Yahoo Finance (NASDAQ:ACUR)
finance.yahoo.com - July 11 at 8:04 AM
publicnow.com logoAcura Pharmaceuticals to Host Webcast on July 14, 2016 to Discuss Additional Data From Study AP-LTX-400 (NASDAQ:ACUR)
www.publicnow.com - July 11 at 6:53 AM
fiscalstandard.com logoNext Weeks Broker Price Targets For Acura Pharmaceuticals, Inc. (ACUR) - Fiscal Standard (NASDAQ:ACUR)
www.fiscalstandard.com - July 10 at 8:04 AM
News IconCompany Stock Lower on the Week Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) - Engelwood Daily (NASDAQ:ACUR)
www.engelwooddaily.com - July 3 at 8:03 AM
realistinvestor.com logoAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Accounts Payable Stands AT $0.375 - RealistInvestor.com (NASDAQ:ACUR)
www.realistinvestor.com - June 29 at 8:26 PM
kcregister.com logoTop News: Tecogen Inc. (NASDAQ:TGEN), Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), Ecology & Environment, Inc ... - KC Register (NASDAQ:ACUR)
www.kcregister.com - June 27 at 3:41 PM
News IconDoes This Provide a Reason to Sell Acura Pharmaceuticals, Inc.? The Stock Has Formed Bearish Multiple Bottom ... - Press Telegraph (NASDAQ:ACUR)
presstelegraph.com - June 27 at 3:41 PM
News IconAcura Pharmaceuticals Incorporated (NASDAQ:ACUR) Shorted Shares Increased By 60.19% - Engelwood Daily (NASDAQ:ACUR)
www.engelwooddaily.com - June 26 at 8:06 AM
ftsenews.co.uk logoAcura Pharmaceuticals, Inc. (ACUR) Updated Price Targets - FTSE News (NASDAQ:ACUR)
www.ftsenews.co.uk - June 24 at 11:17 AM
realistinvestor.com logoAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Accounts Payable Is $0.375 For The Quarter Ended 2016-03-31 - RealistInvestor.com (NASDAQ:ACUR)
www.realistinvestor.com - June 15 at 8:23 PM
kcregister.com logoBest Stocks: Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), Nokia Corporation (ADR) (NYSE:NOK), Facebook Inc ... - KC Register (NASDAQ:ACUR)
www.kcregister.com - June 13 at 3:19 PM
streetinsider.com logoPre-Open Stock Movers 06/09: (ACUR) (CBK) (RADA) Higher; (RH) (INSM) (TMH) Lower (more...) (NASDAQ:ACUR)
www.streetinsider.com - June 11 at 11:30 AM
kcregister.com logoAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) plummeted -6.88%: Spartan Motors Inc. (NASDAQ:SPAR), Illumina Inc ... - KC Register (NASDAQ:ACUR)
www.kcregister.com - June 10 at 11:42 AM
News IconAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Reports Successful Clinical Trials For AP-LTX-400 - Journal Transcript (NASDAQ:ACUR)
www.journaltranscript.com - June 10 at 11:42 AM
smarteranalyst.com logoCompany Update (NASDAQ:ACUR): Acura Pharmaceuticals, Inc's LIMITX(TM) Technology Successfully Confirms Oral ... - Smarter Analyst (NASDAQ:ACUR)
www.smarteranalyst.com - June 8 at 9:25 PM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhib (NASDAQ:ACUR)
biz.yahoo.com - June 8 at 4:38 PM
publicnow.com logoAcura Pharmaceutical's LIMITX(TM) Technology Successfully Confirms Oral Abuse Deterrence Capabilities (NASDAQ:ACUR)
www.publicnow.com - June 8 at 4:28 PM
realistinvestor.com logoAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Has $2.32 Millions Outstanding Debt Accrued - RealistInvestor.com (NASDAQ:ACUR)
www.realistinvestor.com - June 6 at 3:20 PM
News IconAcura Pharmaceuticals, Inc. (ACUR) Do Brokers Advise Buy, Sell Or Hold? - Share Trading News (NASDAQ:ACUR)
www.sharetrading.news - June 1 at 11:39 AM
investornewswire.com logoAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Set To Release Quarterly Earnings - Investor Newswire (NASDAQ:ACUR)
www.investornewswire.com - May 31 at 3:17 PM
investornewswire.com logoAcura Pharmaceuticals, Inc. (NASDAQ:ACUR) Quarterly EPS From Continuing Operations Stands At $-0.2828 - Investor Newswire (NASDAQ:ACUR)
www.investornewswire.com - May 28 at 12:57 PM
publicnow.com logoAcura Pharmaceuticals Announces First Quarter 2016 Financial Results (NASDAQ:ACUR)
www.publicnow.com - May 2 at 4:40 PM
biz.yahoo.com logoQ1 2016 Acura Pharmaceuticals Inc Earnings Release - After Market Close (NASDAQ:ACUR)
biz.yahoo.com - May 2 at 7:07 AM
biz.yahoo.com logoACURA PHARMACEUTICALS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a (NASDAQ:ACUR)
biz.yahoo.com - April 28 at 4:53 PM
publicnow.com logoIndiana Governor's Bill Signing Ceremony Recognizes the Role of Meth-Resistant Technology in Stemming State Meth Problem (NASDAQ:ACUR)
www.publicnow.com - April 28 at 6:28 AM
publicnow.com logoAcura Pharmaceuticals Receives Second U.S. Patent for Novel Limitx(TM) Abuse Deterrent Technology (NASDAQ:ACUR)
www.publicnow.com - April 26 at 4:36 PM

Social

Acura Pharmaceuticals (NASDAQ:ACUR) Chart for Wednesday, August, 24, 2016


Last Updated on 8/24/2016 by MarketBeat.com Staff